Yasser B. Abulhasan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yasser B. Abulhasan has a total of 926 co-authors. Here are the top co-authors by number of shared publications:
Mark R. Angle
Neurological Intensive Care Unit, Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada
8 shared publicationsJeanne Teitelbaum
Neurological Intensive Care Unit, Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada
6 shared publicationsNajayeb Alabdulraheem
Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada
3 shared publicationsCharles Frenette
Infectious Disease Department, McGill University Health Center, Montreal, Quebec, Canada
2 shared publicationsGabrielle Simoneau
Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada
2 shared publicationsIan Schiller
Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada
2 shared publications
Latest Publications
- 10 April 2026
- Published by Springer Nature in Neurocritical Care
- Vol. 45 (2) , 878-879
Intravenous Milrinone after Aneurysmal Subarachnoid Hemorrhage: Is It Time to Be More Aggressive with Treatment Protocols?
- 10 April 2026
- Published by Springer Nature in Neurocritical Care
- Vol. 45 (2) , 878-879
Intravenous Milrinone after Aneurysmal Subarachnoid Hemorrhage: Is It Time to Be More Aggressive with Treatment Protocols?
- Open Access
- 29 January 2026
- Published by Springer Nature in Intensive Care Medicine
- Vol. 52 (2) , 328-330
Melatonin to prevent delirium in the ICU: revisiting the evidence
- 29 January 2026
- Published by Springer Nature in Intensive Care Medicine
- Vol. 52 (2) , 328-330
Open AccessMelatonin to prevent delirium in the ICU: revisiting the evidence
- 19 September 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 101 (12) , 547-548
Author Response: Functional Outcomes and Mortality in Patients With Intracerebral Hemorrhage After Intensive Medical and Surgical Support
- 19 September 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 101 (12) , 547-548
Author Response: Functional Outcomes and Mortality in Patients With Intracerebral Hemorrhage After Intensive Medical and Surgical Support
- 9 May 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (19) , E1985-E1995
Functional Outcomes and Mortality in Patients With Intracerebral Hemorrhage After Intensive Medical and Surgical Support
Background and Objectives: Despite decades of increasingly sophisticated neurocritical care, patient outcomes after spontaneous intracerebral hemorrhage (ICH) remain dismal. Whether this reflects therapeutic nihilism, or the effects of the primary injury has been questioned. In this contemporary cohort, we determined the 30- and 90-day mortality, cause-specific mortality, functional outcome, and the effect of surgical intervention in a culture of aggressive medical and surgical support. Methods: This is a retrospective cohort study of consecutive adult patients with spontaneous ICH admitted to a tertiary neurocritical care unit. Patients with secondary ICH and those subject to limitation-of-care before 72-hours were excluded. For each ICH score, 30- and 90-day mortality, and the modified Rankin Scale (mRS) were examined. The effect of craniotomy/craniectomy ± hematoma evacuation on the outcome of supratentorial ICH was determined using propensity score matching. Median patient follow-up after discharge was 2.2 [IQR, 0.4-4.4] years. Results: Among 319 patients with spontaneous ICH (median age was 69 [IQR, 60-77] years, 60% male), 30- and 90-day mortality were 16% and 22%, respectively, and unfavorable functional outcome (mRS 4-6) was 50% at a median 3.1-months after ICH. Admission predictors of mortality mirrored those of the original ICH score. Unfavorable outcomes for ICH score 3 and 4 were 73% and 86%, respectively. The most common adjudicated primary causes of mortality were direct effect or progression of the ICH (54%), refractory cerebral edema (21%), and medical complications (11%). In matched analyses, lifesaving surgery for supratentorial ICH did not significantly alter mortality or unfavorable functional outcome in patients overall. In subgroup analyses restricted to (1) surgery with hematoma evacuation, and (2) ICH score 3 and 4 patients, the odds of 30-day mortality were reduced by 71% (OR, 0.29, 95% CI, 0.09-0.9, p=0.032) and 80% (OR, 0.2, 95% CI, 0.04-0.91, p=0.038), respectively, but no difference was observed for 90-day mortality or unfavorable functional outcome. Discussion: This study demonstrates that poor outcomes after ICH prevail despite aggressive treatment. Unfavorable outcomes appear related to direct effects of the primary injury and not to premature care limitations. Lifesaving surgery for supratentorial lesions delayed mortality but did not alter functional outcomes.
- 9 May 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (19) , E1985-E1995
Functional Outcomes and Mortality in Patients With Intracerebral Hemorrhage After Intensive Medical and Surgical Support
Background and Objectives: Despite decades of increasingly sophisticated neurocritical care, patient outcomes after spontaneous intracerebral hemorrhage (ICH) remain dismal. Whether this reflects therapeutic nihilism, or the effects of the primary injury has been questioned. In this contemporary cohort, we determined the 30- and 90-day mortality, cause-specific mortality, functional outcome, and the effect of surgical intervention in a culture of aggressive medical and surgical support. Methods: This is a retrospective cohort study of consecutive adult patients with spontaneous ICH admitted to a tertiary neurocritical care unit. Patients with secondary ICH and those subject to limitation-of-care before 72-hours were excluded. For each ICH score, 30- and 90-day mortality, and the modified Rankin Scale (mRS) were examined. The effect of craniotomy/craniectomy ± hematoma evacuation on the outcome of supratentorial ICH was determined using propensity score matching. Median patient follow-up after discharge was 2.2 [IQR, 0.4-4.4] years. Results: Among 319 patients with spontaneous ICH (median age was 69 [IQR, 60-77] years, 60% male), 30- and 90-day mortality were 16% and 22%, respectively, and unfavorable functional outcome (mRS 4-6) was 50% at a median 3.1-months after ICH. Admission predictors of mortality mirrored those of the original ICH score. Unfavorable outcomes for ICH score 3 and 4 were 73% and 86%, respectively. The most common adjudicated primary causes of mortality were direct effect or progression of the ICH (54%), refractory cerebral edema (21%), and medical complications (11%). In matched analyses, lifesaving surgery for supratentorial ICH did not significantly alter mortality or unfavorable functional outcome in patients overall. In subgroup analyses restricted to (1) surgery with hematoma evacuation, and (2) ICH score 3 and 4 patients, the odds of 30-day mortality were reduced by 71% (OR, 0.29, 95% CI, 0.09-0.9, p=0.032) and 80% (OR, 0.2, 95% CI, 0.04-0.91, p=0.038), respectively, but no difference was observed for 90-day mortality or unfavorable functional outcome. Discussion: This study demonstrates that poor outcomes after ICH prevail despite aggressive treatment. Unfavorable outcomes appear related to direct effects of the primary injury and not to premature care limitations. Lifesaving surgery for supratentorial lesions delayed mortality but did not alter functional outcomes.
- 31 August 2022
- Published by Springer Nature in Current Treatment Options in Neurology
- Vol. 24 (9) , 347-363
Management of External Ventricular Drains and Related Complications: a Narrative Review
- 31 August 2022
- Published by Springer Nature in Current Treatment Options in Neurology
- Vol. 24 (9) , 347-363
Management of External Ventricular Drains and Related Complications: a Narrative Review
- 16 August 2022
- Published by Springer Nature in Current Treatment Options in Neurology
- Vol. 24 (10) , 515-531
Treatment of Fever in Neurologically Critically Ill Patients
- 16 August 2022
- Published by Springer Nature in Current Treatment Options in Neurology
- Vol. 24 (10) , 515-531
Treatment of Fever in Neurologically Critically Ill Patients
- 3 November 2021
- Published by Springer Nature in Neurocritical Care
- Vol. 35 (3) , 920-921
Role of Induced Hypertension and Intravenous Milrinone After Aneurysmal Subarachnoid Hemorrhage: Is it Time to Shift the Paradigm?
- 3 November 2021
- Published by Springer Nature in Neurocritical Care
- Vol. 35 (3) , 920-921
Role of Induced Hypertension and Intravenous Milrinone After Aneurysmal Subarachnoid Hemorrhage: Is it Time to Shift the Paradigm?
- 1 March 2021
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 134 (3) , 971-982
Milrinone for refractory cerebral vasospasm with delayed cerebral ischemia
OBJECTIVE: Intravenous (IV) milrinone is a promising option for the treatment of cerebral vasospasm with delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (aSAH). However, data remain limited on the efficacy of treating cases that are refractory to standard therapy with IV milrinone. The aim of this study was to determine predictors of refractory vasospasm/DCI despite treatment with IV milrinone, and to analyze the outcome of rescue therapy with intraarterial (IA) milrinone and/or mechanical angioplasty. METHODS: The authors conducted a retrospective cohort study of all patients with aSAH admitted between 2010 and 2016 to the Montreal Neurological Institute and Hospital. Patients were stratified into 3 groups: no DCI, standard therapy, and rescue therapy. The primary outcome was frequency of DCI-related cerebral infarction identified on neuroimaging before hospital discharge. Secondary outcomes included functional outcome reported as modified Rankin Scale (mRS) score, and segment reversal of refractory vasospasm. RESULTS: The cohort included 322 patients: 212 in the no DCI group, 89 in the standard therapy group, and 21 in the rescue therapy group. Approximately half (52%, 168/322) were admitted with poor-grade aSAH at treatment decision (World Federation of Neurosurgical Societies grade III–V). Among patients with DCI and imaging assessing severity of vasospasm, 62% (68/109) had moderate/severe radiological vasospasm on DCI presentation. Nineteen percent (21/110) of patients had refractory vasospasm/DCI and were treated with rescue therapy. Targeted rescue therapy with IA milrinone reversed 32% (29/91) of the refractory vasospastic vessels, and 76% (16/21) of those patients experienced significant improvement in their neurological status within 24 hours of initiating therapy. Moderate/severe radiological vasospasm independently predicted the need for rescue therapy (OR 27, 95% CI 8.01–112). Of patients with neuroimaging before discharge, 40% (112/277) had developed new cerebral infarcts, and only 21% (23/112) of these were vasospasm-related. Overall, 65% (204/314) of patients had a favorable functional outcome (mRS score 0–2) assessed at a median of 4 months (interquartile range 2–8 months) after aSAH, and there was no difference in functional outcome between the 3 groups (p = 0.512). CONCLUSIONS: The aggressive use of milrinone was safe and effective based on this retrospective study cohort and is a promising therapy for the treatment of vasospasm/DCI after aSAH.
- 1 March 2021
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 134 (3) , 971-982
Milrinone for refractory cerebral vasospasm with delayed cerebral ischemia
OBJECTIVE: Intravenous (IV) milrinone is a promising option for the treatment of cerebral vasospasm with delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (aSAH). However, data remain limited on the efficacy of treating cases that are refractory to standard therapy with IV milrinone. The aim of this study was to determine predictors of refractory vasospasm/DCI despite treatment with IV milrinone, and to analyze the outcome of rescue therapy with intraarterial (IA) milrinone and/or mechanical angioplasty. METHODS: The authors conducted a retrospective cohort study of all patients with aSAH admitted between 2010 and 2016 to the Montreal Neurological Institute and Hospital. Patients were stratified into 3 groups: no DCI, standard therapy, and rescue therapy. The primary outcome was frequency of DCI-related cerebral infarction identified on neuroimaging before hospital discharge. Secondary outcomes included functional outcome reported as modified Rankin Scale (mRS) score, and segment reversal of refractory vasospasm. RESULTS: The cohort included 322 patients: 212 in the no DCI group, 89 in the standard therapy group, and 21 in the rescue therapy group. Approximately half (52%, 168/322) were admitted with poor-grade aSAH at treatment decision (World Federation of Neurosurgical Societies grade III–V). Among patients with DCI and imaging assessing severity of vasospasm, 62% (68/109) had moderate/severe radiological vasospasm on DCI presentation. Nineteen percent (21/110) of patients had refractory vasospasm/DCI and were treated with rescue therapy. Targeted rescue therapy with IA milrinone reversed 32% (29/91) of the refractory vasospastic vessels, and 76% (16/21) of those patients experienced significant improvement in their neurological status within 24 hours of initiating therapy. Moderate/severe radiological vasospasm independently predicted the need for rescue therapy (OR 27, 95% CI 8.01–112). Of patients with neuroimaging before discharge, 40% (112/277) had developed new cerebral infarcts, and only 21% (23/112) of these were vasospasm-related. Overall, 65% (204/314) of patients had a favorable functional outcome (mRS score 0–2) assessed at a median of 4 months (interquartile range 2–8 months) after aSAH, and there was no difference in functional outcome between the 3 groups (p = 0.512). CONCLUSIONS: The aggressive use of milrinone was safe and effective based on this retrospective study cohort and is a promising therapy for the treatment of vasospasm/DCI after aSAH.
- 28 May 2020
- Published by Springer Nature in Neurocritical Care
- Vol. 33 (1) , 13-19
Neurocritical Care Resource Utilization in Pandemics: A Statement by the Neurocritical Care Society
- 28 May 2020
- Published by Springer Nature in Neurocritical Care
- Vol. 33 (1) , 13-19
Neurocritical Care Resource Utilization in Pandemics: A Statement by the Neurocritical Care Society
- 27 September 2019
- Published by Springer Nature in Neurocritical Care
- Vol. 32 (3) , 836-846
Health Care-Associated Infections in a Neurocritical Care Unit of a Developing Country
Health care-associated infections (HAIs) in intensive care units (ICUs) specialized for neurocritical care (neurocritical care units [NCCUs]) are serious yet preventable complications that contribute significantly to morbidity and mortality worldwide. However, reliable data are scarcely available from the developing world. We aimed to analyze the incidence, epidemiology, microbial etiology, and outcomes of HAIs in an NCCU of a tertiary care teaching hospital in a high-income, developing country.
- 27 September 2019
- Published by Springer Nature in Neurocritical Care
- Vol. 32 (3) , 836-846
Health Care-Associated Infections in a Neurocritical Care Unit of a Developing Country
Health care-associated infections (HAIs) in intensive care units (ICUs) specialized for neurocritical care (neurocritical care units [NCCUs]) are serious yet preventable complications that contribute significantly to morbidity and mortality worldwide. However, reliable data are scarcely available from the developing world. We aimed to analyze the incidence, epidemiology, microbial etiology, and outcomes of HAIs in an NCCU of a tertiary care teaching hospital in a high-income, developing country.